Azitra is trading 9.78% down at $0.82, with no confirmed company-specific announcement explaining the pre-market decline. - It closed at $0.90 on October 28. - An October 26 update reported positive ex vivo ATR-COSF results; initial human-study results are anticipated by year-end, but that earlier news does not explain the current decline. - Nasdaq futures are also lower, though available evidence does not establish a direct link to Azitra’s move.